The role of glutamate in dementia

2012 | book part

Jump to:Cite & Linked | Documents & Media | Details | Version history

Cite this publication

​The role of glutamate in dementia​
Kornhuber, J.  & Wiltfang, J. ​ (2012)
In:​Jellinger, Kurt; Fazekas, F.; Windisch, Manfred​ (Eds.), Ageing and Dementia. ​Vienna: ​Springer. DOI: https://doi.org/10.1007/978-3-7091-6467-9_24 

Documents & Media

License

GRO License GRO License

Details

Authors
Kornhuber, J. ; Wiltfang, Jens 
Editors
Jellinger, Kurt; Fazekas, F.; Windisch, Manfred
Abstract
Glutamate is an excitatory neurotransmitter, but may also act as an endogenous neurotoxin. There is good evidence for an involvement of the glutamatergic system in the pathophysiology of dementia. The glutamatergic transmission machinery is quite complex and provides a gallery of possible drug targets. There are good arguments both for an agonist and an antagonist strategy. When following the antagonist strategy, the goal is to provide neuroprotective effects via glutamate receptor antagonisms without inhibiting the physiological transmission that is required for learning and memory formation. When following the agonist strategy, the goal is to activate glutamatergic transmission without neurotoxic side effects. Several available antidementia drugs may modulate the glutamatergic transmission.The pathogenesis of the most frequent type of dementia, i.e. Alzheimer’s disease, is poorly understood. Currently, there is an enormous need for an effective pharmacotherapy that either slows the rate of progression or produces clinically significant improvement in symptoms. This short overview describes the role of the excitatory neurotransmitter glutamate in Alzheimer’s disease. Glutamate is the transmitter used, e.g., in corticocortical association neurons and in intrahippocampal fibers. Glutamatergic mechanisms are involved in fast synaptic transmission as well as in learning and memory processes. But, under certain conditions, glutamate may become a neurotoxin leading to slowly progressive as well as acute neuronal cell loss. These properties of the glutamatergic system led to the hypothesis that there might be a glutamatergic strategy for the treatment of Alzheimer’s disease and also other dementia syndromes
Issue Date
2012
Publisher
Springer
ISBN
978-3-211-83114-4
Language
English

Reference

Citations


Social Media